<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20200909048672N2</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2023-01-03</date_registration>
      <primary_sponsor>Esfahan University of Medical Sciences</primary_sponsor>
      <public_title>evaluation of the therapeutic effect of hemorrhidoplasty laser in hemorrhides</public_title>
      <acronym></acronym>
      <scientific_title>A Comparative Study between the Therapeutic Results of Laser Hemorrhoidoplasty and Milligan-Morgan’s Open Surgical Hemorrhoidectomy in Patients with Hemorrhoids</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2022-09-23</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>100</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/59095</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: First, in the form of consecutive sampling, before the operation the patients go to the surgical clinic one by one , and then the surgeon checks the inclusion and exclusion criteria, and if it was appropriate, he randomly places  patients in group A or B, so that ,The first person takes the last digit on the right side using the random function of calculator, and if the number is even, the person enters group A, and if the number is odd, he enters group B, and the second person is the opposite .</study_design>
      <phase>N/A</phase>
      <hc_freetext>Condition 1: Anal Hemorrhoid Grade III. Condition 2: Anal Hemorrhoid Grade IV.</hc_freetext>
      <i_freetext>Intervention 1: Control group: Hemorrhoidectomy in Milligan Morgan procedure. Intervention 2: Intervention group: Laser Hemorrhoidoplasty. To perform the procedure in the intervention group, a 23 mm Proctoscope will be inserted into the anal canal and a Doppler probe will search to find the upper rectal artery located 3 cm above the dentate line. Once found, a 600micron optical fiber will subcutaneously be inserted into hemorrhoid through a 1 mm opening created with electrocautery in the anal vein (near the hemorrhoid base). Through optical fiber, then the laser device will be inserted into hemorrhoid and the coagulation occurs. Each shot has a power of 13 watts and a duration of 1.2 seconds. For each vessel, 5 shots will be fired 0.6 seconds apart. The other vessels will then be coagulated in a clockwise manner. The patient will be discharged 6-24 hours after surgery, depending on their physical condition.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
All the data obtained from the study, including the data of the patients and statistical analysis maps and the results obtained after the official request from the competent authorities, will be provided to them.

When:
From the time of publication of the article for an unlimited period

To whom:
Official requests are answered from academic authorities and accredited scientific institutions and approved industrial centers.

Conditions:
The data can be used to advance science in future articles or books, as well as to improve treatment methods with the help of new tools.

Where to obtain:
Dr Reza Eshraghi
eshraghireza@med.mui.ac.ir

How to obtain:
Data will be announced after the approval of the main author of the article and the approval of the Research and Development Vice-Chancellor of Isfahan University of Medical Sciences

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Reza Eshraghi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Alzahra hospital-Sofeh Blvd</address>
        <city>Isfahan</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>8174673461</zip>
        <telephone>+98 913 300 2036</telephone>
        <email>eshraghireza@med.mui.ac.ir</email>
        <affiliation>Esfahan University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Reza Eshraghi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Alzahra hospital-Sofeh Blvd</address>
        <city>Isfahan</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>8174673461</zip>
        <telephone>+98 913 300 2036</telephone>
        <email>eshraghireza@med.mui.ac.ir</email>
        <affiliation>Esfahan University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>aged &gt; 18 years
grade III, IV hemorrhoids
non-respondent to medical treatment
willing to participate in the study</inclusion_criteria>
      <agemin>no limit</agemin>
      <agemax>no limit</agemax>
      <gender>Both</gender>
      <exclusion_criteria>patients with Fissure
patients with Fistula
patients with Coagulation disorder
substance abuse
Irritable bowel disease
patients who had hemorrhoid surgery treatment earlier</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>K64.2</hc_code>
      <hc_code>K64.3</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Third degree hemorrhoids</hc_keyword>
      <hc_keyword>Fourth degree hemorrhoids</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Surgery</i_code>
      <i_code>Treatment - Surgery</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Control group: Hemorrhoidectomy in Milligan Morgan procedure</i_keyword>
      <i_keyword>Intervention group: Laser Hemorrhoidoplasty. To perform the procedure in the intervention group, a 23 mm Proctoscope will be inserted into the anal canal and a Doppler probe will search to find the upper rectal artery located 3 cm above the dentate line. Once found, a 600micron optical fiber will subcutaneously be inserted into hemorrhoid through a 1 mm opening created with electrocautery in the anal vein (near the hemorrhoid base). Through optical fiber, then the laser device will be inserted into hemorrhoid and the coagulation occurs. Each shot has a power of 13 watts and a duration of 1.2 seconds. For each vessel, 5 shots will be fired 0.6 seconds apart. The other vessels will then be coagulated in a clockwise manner. The patient will be discharged 6-24 hours after surgery, depending on their physical condition.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Pain. Timepoint: Before intervention and 1st, 4th and 12th weeks after intervention. Method of measurement: Visual Analogue Scale questionnaire.</prim_outcome>
      <prim_outcome>Itching. Timepoint: Before intervention and 1st, 4th and 12th weeks after intervention. Method of measurement: asking the questions from patients.</prim_outcome>
      <prim_outcome>Bleeding. Timepoint: Before intervention and 1st, 4th and 12th weeks after intervention. Method of measurement: asking the questions from patients.</prim_outcome>
      <prim_outcome>Complications. Timepoint: 1st, 4th and 12th weeks after intervention. Method of measurement: Visit by attending physician and asking the questions from patients.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Esfahan University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2021-09-21</approval_date>
        <contact_name>Research Ethics Committees of School of Medicine - Isfahan University of Medical Sciences</contact_name>
        <contact_address>Isfahan University of Medical Since- Hezar jirib Street- Isfahan Isfahan Isfehan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
